论文部分内容阅读
目的探讨尿激酶UK对急性脑梗死的疗效及其安全性。方法 76例ACI患者随机分为治疗组和对照组,各38例。两组均给予降低颅内压,减轻脑水肿,处理并发症等基础治疗,在维持水、电解质平衡及综合治疗的基础上,治疗组给予尿激酶。比较两组神经功能缺损情况及临床疗效。结果治疗组治疗后各时期神经功能改善情况均明显优于对照组,且治疗组总有效率明显高于对照组,差异均有统计学意义(P<0.05)。结论尿激酶静脉溶栓治疗疗效优于单纯常规内科综合治疗,且神经功能恢复时间显著缩短,是一种有效、安全的治疗方法,值得在临床上进一步推广应用。
Objective To investigate the efficacy and safety of urokinase UK on acute cerebral infarction. Methods 76 cases of ACI patients were randomly divided into treatment group and control group, 38 cases each. Both groups were given to reduce intracranial pressure, reduce brain edema, treatment of complications and other basic treatment, maintaining water and electrolyte balance and comprehensive treatment based on the treatment group given urokinase. The neurological deficits and clinical outcomes were compared between the two groups. Results After treatment, the improvement of neurological function in the treatment group was significantly better than that in the control group, and the total effective rate in the treatment group was significantly higher than that in the control group (P <0.05). Conclusion The efficacy of intravenous thrombolytic therapy of urokinase is superior to that of conventional medical therapy alone. The recovery time of neurological function is significantly shortened. It is an effective and safe treatment and should be further popularized and applied in clinic.